Chengdu Anjian Likang Biotechnology Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Chengdu Anjian Likang Biotechnology Co., Ltd. - overview
Established
2025
Location
Chengdu, Sichuan, China
Primary Industry
Biotechnology
About
Based in Chengdu, China and founded in 2025, Chengdu Anjian Likang Biotechnology Co. , Ltd. provides drug discovery solutions for the healthcare industry. The company was established to focus on the research and innovation of ENDOD1 small molecule inhibitors.
In January 2026, the company closed a series A funding round from CDHT Hi-Tech Venture and Orinno Capital. The company works with medical researchers to provide small molecule inhibitors" and develops "ENDOi," a targeted drug that has shown progression-free, partial, or complete response results in treating high grade serous ovarian cancer and advanced pancreatic cancer. The company’s revenue is generated by the research and development of biopharmaceutical products. The company plans to accelerate the research and development of its ENDOD1 small molecule inhibitors, specifically aiming to submit IND applications in China and the United States in 2026 and to expand its market layout.
Current Investors
CDHT Hi-Tech Venture, Orinno Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.